Biomarker-Based Management of AKI: Fact or Fantasy?

New biomarkers for acute kidney injury (AKI) have improved our understanding of the etiology and pathogenesis of AKI. Depending on their origin, function, and kinetic profile, biomarkers have a role in screening, diagnosis, prognostication, and monitoring of AKI. This offers opportunities to improve the management of AKI, but concerns and limitations remain. In this review, we summarize the current role of new AKI biomarkers in the management of AKI and outline some of the ongoing limitations and challenges.

Automated summary

New biomarkers for AKI have improved our understanding of the disease, playing a role in screening, diagnosis, prognosis, and monitoring. Despite offering opportunities for better management of AKI, concerns and limitations remain.